» Articles » PMID: 28373814

Myeloid-derived Suppressor Cells in Gliomas

Overview
Publisher Termedia
Specialty Oncology
Date 2017 Apr 5
PMID 28373814
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of early myeloid progenitors and precursors at different stages of differentiation into granulocytes, macrophages, and dendritic cells. Blockade of their differentiation into mature myeloid cells in cancer results in an expansion of this population. High-grade gliomas are the most common malignant tumours of the central nervous system (CNS), with a poor prognosis despite intensive radiation and chemotherapy. Histopathological and flow cytometry analyses of human and rodent experimental gliomas revealed the extensive heterogeneity of immune cells infiltrating gliomas and their microenvironment. Immune cell infiltrates consist of: resident (microglia) and peripheral macrophages, granulocytes, myeloid-derived suppressor cells, and T lymphocytes. Intratumoural density of glioma-associated MDSCs correlates positively with the histological grade of gliomas and patient's survival. MDSCs have the ability to attract T regulatory lymphocytes to the tumour, but block the activation of tumour-reactive CD4 T helper cells and cytotoxic CD8 T cells. Immunomodulatory mechanisms employed by malignant gliomas pose an appalling challenge to brain tumour immunotherapy. In this mini-review we describe phenotypic and functional characteristics of MDSCs in humans and rodents, and their occurrence and potential roles in glioma progression. While understanding the complexity of immune cell interactions in the glioma microenvironment is far from being accomplished, there is significant progress that may lead to the development of immunotherapy for gliomas.

Citing Articles

Immunotherapeutic advances in glioma management: The rise of vaccine-based approaches.

Awuah W, Shah M, Tan J, Ranganathan S, Sanker V, Darko K CNS Neurosci Ther. 2024; 30(9):e70013.

PMID: 39215399 PMC: 11364516. DOI: 10.1111/cns.70013.


Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond.

Afzal A, Afzal Z, Bizink S, Davis A, Makahleh S, Mohamed Y Curr Issues Mol Biol. 2024; 46(8):7795-7811.

PMID: 39194679 PMC: 11352848. DOI: 10.3390/cimb46080462.


Forms of Non-Apoptotic Cell Death and Their Role in Gliomas-Presentation of the Current State of Knowledge.

Nafe R, Hattingen E Biomedicines. 2024; 12(7).

PMID: 39062119 PMC: 11274595. DOI: 10.3390/biomedicines12071546.


Non-Tumor Cells within the Tumor Microenvironment-The "Eminence Grise" of the Glioblastoma Pathogenesis and Potential Targets for Therapy.

Bugakova A, Chudakova D, Myzina M, Yanysheva E, Ozerskaya I, Soboleva A Cells. 2024; 13(10.

PMID: 38786032 PMC: 11119139. DOI: 10.3390/cells13100808.


Cellular Components of the Tumor Environment in Gliomas-What Do We Know Today?.

Nafe R, Hattingen E Biomedicines. 2024; 12(1).

PMID: 38275375 PMC: 10813739. DOI: 10.3390/biomedicines12010014.


References
1.
Nagaraj S, Gabrilovich D . Myeloid-derived suppressor cells in human cancer. Cancer J. 2010; 16(4):348-53. DOI: 10.1097/PPO.0b013e3181eb3358. View

2.
Youn J, Gabrilovich D . The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010; 40(11):2969-75. PMC: 3277452. DOI: 10.1002/eji.201040895. View

3.
Wainwright D, Dey M, Chang A, Lesniak M . Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol. 2013; 4:116. PMC: 3654236. DOI: 10.3389/fimmu.2013.00116. View

4.
Pak A, Wright M, Matthews J, Collins S, Petruzzelli G, Young M . Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995; 1(1):95-103. View

5.
Otvos B, Silver D, Mulkearns-Hubert E, Alvarado A, Turaga S, Sorensen M . Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells. 2016; 34(8):2026-39. PMC: 5820763. DOI: 10.1002/stem.2393. View